Efficacy and Incidence of Treatment-Related Adverse Events of Thrombopoietin Receptor Agonists in Adults with Immune Thrombocytopenia: A Systematic Review and Network Meta-Analysis of Randomized Controlled Study
Acta Haematologica · 2023 · 146 (3) · 173-184
DOI: 10.1159/000528642 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift Acta Haematologica, online erschienen am 26.12.2022. Verfasst von Yin Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Epidemiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Henan Engineering Research Center …. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia. Die Arbeit wurde bisher 12-mal zitiert (Crossref).
Themen: Patientensicherheit
Abstract (Originalsprache)
Introduction
The aim of the study was to conduct a network meta-analysis to assess the efficacy and incidence of treatment-related adverse events (TRAEs) of eltrombopag, romiplostim, avatrombopag, recombinant human thrombopoietin (rhTPO), and hetrombopag for adult immune thrombocytopenia (ITP).
Methods
Randomized controlled trials (RCTs) of the five therapies from inception to June 1, 2022, were included. The efficacy outcome was the rate of platelet response, defined as the achievement of platelet counts above 50 × 109/L. Pairwise odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. The surface under the cumulative ranking (SUCRA) was used to rank the included therapies for each outcome.
Results
In total, 1,360 participants were analyzed in 14 eligible RCTs. All of the therapies showed a significantly better platelet response than the placebo, and avatrombopag (OR, 7.42; 95% CI: 1.74–31.69) and rhTPO (OR, 3.86; 95% CI: 1.62–9.18) were better than eltrombopag. Regarding TRAEs, no significant differences were found between patients receiving eltrombopag, romiplostim, and avatrombopag. Avatrombopag carried the highest platelet response rate with SUCRA value of 87.5, and carried the least TRAEs risk with SUCRA value of 37.0.
Conclusions
These findings indicated that avatrombopag appeared to be the optimal choice as the second-line therapy for adult ITP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer Epidemiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Henan Engineering Research Center of Cancer Prevention and Control, Henan International Joint Laboratory…
- Beijing Ditan Hospital, Capital Medical University, Chaoyang, China.
- Yinchuan Hospital of Stomatology, Yinchuan, China.
Zitieren
APA
Liu, Y., Zhang, H. X., Su, J., Geng, Q. C., Lin, X., & Feng, C. X. (2023). Efficacy and Incidence of Treatment-Related Adverse Events of Thrombopoietin Receptor Agonists in Adults with Immune Thrombocytopenia: A Systematic Review and Network Meta-Analysis of Randomized Controlled Study. Acta Haematologica, 146(3), 173-184. https://doi.org/10.1159/000528642
Vancouver
Liu Y, Zhang HX, Su J, Geng QC, Lin X, Feng CX. Efficacy and Incidence of Treatment-Related Adverse Events of Thrombopoietin Receptor Agonists in Adults with Immune Thrombocytopenia: A Systematic Review and Network Meta-Analysis of Randomized Controlled Study. Acta Haematologica. 2023;146(3):173-184. doi:10.1159/000528642
BibTeX
@article{Liu2023,
author = {Liu, Yin and Zhang, Han-Xi and Su, Juan and Geng, Qing-Chao and Lin, Xin and Feng, Chen-Xi},
title = {Efficacy and Incidence of Treatment-Related Adverse Events of Thrombopoietin Receptor Agonists in Adults with Immune Thrombocytopenia: A Systematic Review and Network Meta-Analysis of Randomized Controlled Study},
journal = {Acta Haematologica},
year = {2023},
volume = {146},
number = {3},
pages = {173--184},
doi = {10.1159/000528642}
}
EUVIMED